用于治疗骨关节炎的关节内纳米药物递送策略。
Intra-articular nanodrug delivery strategies for treating osteoarthritis.
作者信息
Zhou Dongyang, Zhou Fengjin, Sheng Shihao, Wei Yan, Chen Xiao, Su Jiacan
机构信息
Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; Institute of Advanced Interdisciplinary Materials Science, Shanghai University, Shanghai 200444, China; College of Medicine, Shanghai University, Shanghai 200444, China; Organoid Research Center, Shanghai University, Shanghai 200444, China.
Department of Orthopaedics, Honghui Hospital, Xi'an Jiao Tong University, Xi'an 710000, China.
出版信息
Drug Discov Today. 2023 Mar;28(3):103482. doi: 10.1016/j.drudis.2022.103482. Epub 2022 Dec 27.
Osteoarthritis (OA) is characterized by progressive cartilage degeneration. Pharmaceutical intervention remains a main treatment approach. However, drug delivery via intra-articular administration (IA) can be restricted by rapid clearance, the dense and highly negatively charged extracellular matrix (ECM) of cartilage, and uneven distribution of diseased chondrocytes. Nanodrug delivery systems, such as liposomes, micelles, and nanoparticles (NPs), have shown great potential to prolong intra-articular residence, penetrate the ECM, and achieve diseased chondrocyte-specific delivery. In this review, we discuss the challenges associated with intra-articular drug delivery in OA and the nanodrug delivery strategies developed to overcome these challenges. It is anticipated that these nanodrug delivery strategies will advance IA of drugs into broader applications in OA treatment.
骨关节炎（OA）的特征是软骨进行性退变。药物干预仍然是主要的治疗方法。然而，通过关节内给药（IA）进行药物递送可能会受到快速清除、软骨致密且高度带负电荷的细胞外基质（ECM）以及病变软骨细胞分布不均的限制。纳米药物递送系统，如脂质体、胶束和纳米颗粒（NPs），已显示出在延长关节内停留时间、穿透ECM以及实现病变软骨细胞特异性递送方面的巨大潜力。在本综述中，我们讨论了OA关节内药物递送相关的挑战以及为克服这些挑战而开发的纳米药物递送策略。预计这些纳米药物递送策略将推动药物关节内给药在OA治疗中得到更广泛的应用。
Zotero 插件